Tekmira Pharmaceuticals will supply one of its experimental Ebola treatments for clinical studies to be conducted in West Africa.» Read More
Another large shareholder of Botox-maker Allergan is expressing concern over the company's corporate governance amid its fight to hold off hostile acquirer Valeant.
Kadmon, the drug company founded by Sam Waksal of ImClone and Martha Stewart fame, is starting to look more and more like its founder's last company.
GlaxoSmithKline said on Thursday it had chosen Philip Hampton, who currently chairs Royal Bank of Scotland, as its next chairman.
"The stock is correct in going higher" in response to the deal, says CNBC's Jim Cramer.
Banned ImClone founder Sam Waksal's new biotech company, Kadmon, has plans to go public. The company aims to file with the SEC by the end of this year.
The US government has been promising a crackdown on tax inversion deals for months. Yet the measures announced Monday may not be disincentive enough.
Merck agrees to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.
Karl Ludwig-Kley Merck KGAA, and Rakesh Sachdev, Sigma-Aldrich president & CEO, discuss Merck's acquisition of Sigma-Aldrich and the future of life sciences and technology.
An erectile dysfunction drug that reduces by half the time patients need to take the pill has been approved by the U.S. Food and Drug Administration.
New York Attorney General Eric Schneiderman's suit against Actavis may have far-reaching implications for other drugmakers.
The NY AG has filed an anti-trust lawsuit on Actavis' strategy for its Alzheimer's drug. CNBC's Meg Tirrell reports the controversy over "Namenda."
U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments.
William Ackman criticized Allergan's board of directors, urging them to "wake up" and at least listen to potential purchaser Valeant Pharmaceuticals.
Ilan Ganot left his banking job to form a company to develop drugs to treat his 4-year-old son, who has Duchenne muscular dystrophy.
Ilan Ganot, Solid Ventures, discusses the company's ongoing efforts to develop treatments for Duchenne muscular dystrophy through gene therapy.
CNBC's Meg Tirrell has the story of one dad who quit his job and founded a biotech company in hopes of bringing therapies to market for rare diseases.
Gilead is already among the 10 best performers in the Nasdaq 100 this year. So can anything slow this behemoth down? If you ask the analysts, it sounds unlikely.
Three biotech stocks have plenty of potential, John Schroer of Allianz Global Investors says.
U.S. regulators granted accelerated approval to Merck's Keytruda drug, a new type of melanoma treatment for patients with advanced melanoma.
Johnson & Johnson executive Joaquin Duato said the company wants to help save lives by fast tracking its Ebola vaccine.
Get the best of CNBC in your inbox